News
RHHBY
39.63
-0.83%
-0.33
Gene editors steady despite latest leadership shake-up at FDA
Seeking Alpha · 14m ago
DIARY-Europe's STOXX 600 corporate earnings week ahead
Reuters · 2h ago
Lower interest rates, drug pricing reform clarity are catalysts for biotech M&A market
Seeking Alpha · 19h ago
From $172 to $20: Sarepta's Spectacular Fall
NASDAQ · 1d ago
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
Seeking Alpha · 1d ago
MAIA Biotechnology in pact with Roche for cancer treatments
Seeking Alpha · 1d ago
Sarepta Stock (SRPT) Could Soar 200% Despite Growing Caution on Wall Street
TipRanks · 1d ago
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
TipRanks · 1d ago
FDA's Makary talks up modernizing agency to get drugs to market faster
Seeking Alpha · 2d ago
FDA to launch national vouchers to cut drug review time
Seeking Alpha · 2d ago
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
NASDAQ · 2d ago
Roche And Prothena: Why Moving On Makes Sense
Seeking Alpha · 2d ago
Trump administration weighs crackdown on pharma ads, Bloomberg says
TipRanks · 2d ago
Swiss stocks - Factors to watch on June 17
Reuters · 3d ago
Genentech And AbbVie: Venclexta Combo Fails To Extend Survival In Phase III Trial For High-Risk MDS
NASDAQ · 3d ago
Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue
Seeking Alpha · 3d ago
UBS Keeps Their Buy Rating on Roche Holding AG (RHHVF)
TipRanks · 3d ago
Roche, AbbVie say Phase III VERONA study faliled in MDS
TipRanks · 3d ago
BUZZ-AbbVie stock dips after cancer drug trial setback
Reuters · 3d ago
Roche, AbbVie says Phase III VERONA study faliled in MDS
TipRanks · 3d ago
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.